Skip to main content
. Author manuscript; available in PMC: 2014 Aug 15.
Published in final edited form as: Clin Cancer Res. 2013 Jun 28;19(16):4455–4464. doi: 10.1158/1078-0432.CCR-13-0127

Figure 3. Alda-89 does not promote HNC growth in vitro or in vivo.

Figure 3

Panel A: Cell growth curves in culture for SAS cells treated with vehicle, 60 µM or 600 µM Alda-89. Panel B: Clonogenic survival assay showing that 8 Gy RT dramatically reduced the SAS and SCC90 cell survival normalized to the control group. Alda-89 treatment did not affect RT cell kill compared to vehicle control. Panel C: Clonogenic survival assay showing that fractionated RT of 3Gy/fraction/d for 4 consecutive days dramatically reduced the SAS, SCC90 and SCC1 cell survival normalized to the control group. Alda-89 treatment did not affect RT induced cell death compared to vehicle control. Panel D: SAS xenograft tumor growth curves over time. Treatment with Alda-89 at 100 uM/day did not accelerate the tumor growth in vivo compared to the vehicle. Panel E: SAS xenograft tumor growth curves over time after 12 Gy radiation. Treatment with Alda-89 at 100 mg/kg/day did not accelerate the tumor growth in vivo compared to the vehicle control.